1. ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose
- Author
-
Xuelei Song, Ching H. Chang, Zhu Chen, Raffaele Ingenito, Edith Monteagudo, Simone Bufali, Silvi Luell, Roger Meurer, Francesca Rech, Ester Carballo-Jane, Jun Wang, Simona Cianetti, Maria Verdirame, Elisabetta Bianchi, Alison M. Strack, Suzanne S. Eveland, Karen Gagen, Marina Ichetovkin, Elena Capito, Annunziata Langella, Fabio Bonelli, Antonello Pessi, Betsy Frantz-Wattley, Maria Veneziano, Charlotte Burton, Brian K. Hubbard, Edward A. O'Neill, and Xun Chen
- Subjects
Very low-density lipoprotein ,Clinical Biochemistry ,Pharmaceutical Science ,Peptide ,High-Density Lipoproteins, Pre-beta ,Biochemistry ,Mice ,Structure-Activity Relationship ,chemistry.chemical_compound ,Drug Discovery ,polycyclic compounds ,Animals ,Humans ,Molecular Biology ,Triglycerides ,chemistry.chemical_classification ,Apolipoprotein A-I ,biology ,Triglyceride ,Cholesterol ,Molecular Mimicry ,Organic Chemistry ,Reverse cholesterol transport ,nutritional and metabolic diseases ,Peptide Fragments ,Amino acid ,chemistry ,ABCA1 ,biology.protein ,Molecular Medicine ,lipids (amino acids, peptides, and proteins) ,Lipoproteins, HDL ,Ex vivo - Abstract
Reverse cholesterol transport promoted by HDL-apoA-I is an important mechanism of protection against atherosclerosis. We have previously identified apoA-I mimetic peptides by synthesizing analogs of the 22 amino acid apoA-I consensus sequence (apoA-Icons) containing non-natural aliphatic amino acids. Here we examined the effect of different aliphatic non-natural amino acids on the structure–activity relationship (SAR) of apoA-I mimetic peptides. These novel apoA-I mimetics, with long hydrocarbon chain (C5–8) amino acids incorporated in the amphipathic α helix of the apoA-Icons, have the following properties: (i) they stimulate in vitro cholesterol efflux from macrophages via ABCA1; (ii) they associate with HDL and cause formation of pre-β HDL particles when incubated with human and mouse plasma; (iii) they associate with HDL and induce pre-β HDL formation in vivo, with a corresponding increase in ABCA1-dependent cholesterol efflux capacity ex vivo; (iv) at high dose they associate with VLDL and induce hypertriglyceridemia in mice. These results suggest our peptide design confers activities that are potentially anti-atherogenic. However a dosing regimen which maximizes their therapeutic properties while minimizing adverse effects needs to be established.
- Published
- 2010
- Full Text
- View/download PDF